Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
Optimized Fc variants
US11820830B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11820830-B2 |
| Application number | US-202016942615-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 29, 2020 |
| Priority date | Jul 20, 2004 |
| Publication date | Nov 21, 2023 |
| Grant date | Nov 21, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
First claim
Opening claim text (preview).
We claim: 1. A nucleic acid encoding a polypeptide comprising an Fc variant of a wild-type parent Fc polypeptide, wherein said Fc variant comprises amino acid substitutions at positions 236 and 239 in the Fc region, wherein numbering is according to the EU index. 2. A nucleic acid encoding a heavy chain of an antibody comprising an Fc variant of a wild-type parent Fc polypeptide, wherein said Fc variant comprises amino acid substitutions at positions 236 and 239 in the Fc region, wherein numbering is according to the EU index. 3. The nucleic acid according to claim 2 , wherein the amino acid substitution at position 236 is 236A. 4. The nucleic acid according to claim 2 , wherein the amino acid substitution at position 239 is 239D. 5. The nucleic acid according to claim 2 , wherein said Fc variant comprises amino acid substitutions 236A/239D. 6. The nucleic acid according to claim 2 , wherein said Fc variant comprises amino acid substitutions 236A/239D/332E. 7. The nucleic acid according to claim 2 , wherein said parent Fc polypeptide is a human IgG1 Fc polypeptide. 8. The nucleic acid according to claim 2 , wherein said antibody is a monoclonal antibody. 9. An expression vector comprising the nucleic acid according to claim 2 . 10. An expression vector comprising the nucleic acid according to claim 5 . 11. An expression vector comprising the nucleic acid according to claim 6 . 12. A host cell comprising the nucleic acid according to claim 2 . 13. A host cell comprising the nucleic acid according to claim 5 . 14. A host cell comprising the nucleic acid according to claim 6 . 15. A host cell comprising the expression vector according to claim 9 . 16. A host cell comprising the expression vector according to claim 10 . 17. A host cell comprising the expression vector according to claim 11 . 18. A method of producing a polypeptide comprising: a) culturing the host cell according to claim 12 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide. 19. A method of producing a polypeptide comprising: a) culturing the host cell according to claim 13 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide. 20. A method of producing a polypeptide comprising: a) culturing the host cell according to claim 14 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide. 21. A method of producing a polypeptide comprising: a) culturing the host cell according to claim 15 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide. 22. A method of producing a polypeptide comprising: a) culturing the host cell according to claim 16 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide. 23. A method of producing a polypeptide comprising: a) culturing the host cell according to claim 17 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide.
Assignees
Inventors
Classifications
- C07K16/2887Primary
against CD20 · CPC title
the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment · CPC title
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title
against material from animals or humans · CPC title
against receptors for growth factors, growth regulators · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11820830B2 cover?
- The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
- Who is the assignee on this patent?
- Xencor Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2887. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).